Unique Collaborative Research Program Between Novartis And Leukaemia Physicians Across Europe Moves CML Management Forward

Data on 2,500 patients with chronic myeloid leukaemia (CML) and results from state-of-the art monitoring are providing new insights into the management of the condition, according to one-year data from a unique collaborative research programme designed to optimise the treatment and monitoring of patients throughout Europe. The